- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06065436
Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease
April 12, 2024 updated by: Tobias S. Kohler, MD, MPH, Mayo Clinic
Impact of Concurrent Low Intensity Shockwave Therapy on Clinical Outcomes With Collagenase Clostridium Histolyticum in Peyronie's Disease: A Randomized Controlled Trial
The purpose of this research is to determine whether or not low-intensity shockwave therapy (LiSWT) with Xiaflex treatment will result in greater improvements to the curvature of the penis.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wyatt H Anians, CCRP
- Phone Number: 507-538-6151
- Email: Anians.Wyatt@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic Minnesota
-
Contact:
- Wyatt H Anians, CCRP
- Phone Number: 507-538-6151
- Email: Anians.Wyatt@mayo.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria
• Diagnosed with PD
- Palpable penile plaque
- Dorsal, lateral, or dorsolateral penile curvature
- Penile curvature > 30 degrees and < 90 degrees as measured using goniometer during objective curvature assessment
- Non-calcified plaque or grade 1 calcification ("stippling", no shadowing) as determined by penile duplex Doppler ultrasound (PDDU)
- "Stable PD symptoms' defined as PD symptom duration > 6-months or stable symptoms > 3-months
Exclusion Criteria:
- Prior intralesional injections or surgery for PD.
- Severe baseline penile pain.
- Moderate or severe baseline ED based on IIEF-EF domain.
- History of low intensity shockwave therapy for sexual dysfunction (ED or PD).
- Ventral (downward) or ventrolateral penile curvature.
- Moderate or severe (grade 2/3) plaque calcification as determined by PDDU.
- Inability to achieve satisfactory erection rigidity at time of baseline curvature assessment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Collagenase Clostridium Histolyticum with Low Intensity Shockwave Therapy
Subjects will receive Collagenase Clostridium Histolyticum (CCH) intralesional injection with low-intensity shockwave therapy (LiSWT).
|
Total of 8 Intralesional injection (0.90 mg), administered as four separate injection series.
Within each series, subjects will receive two injections, administered approximately 1-7 days apart.
Other Names:
Single low intensity shockwave therapy consistent of 1,500 shocks at a rate of 120 shocks/minute and using a power setting of 0.09 mJ/mm2.
These treatments will occur four separate times, before each of the four separate CCH injection series.
|
Active Comparator: Collagenase Clostridium Histolyticum
Subjects will receive Collagenase Clostridium Histolyticum (CCH) intralesional injection per standard of care.
|
Total of 8 Intralesional injection (0.90 mg), administered as four separate injection series.
Within each series, subjects will receive two injections, administered approximately 1-7 days apart.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in symptom bother
Time Frame: Baseline, 6 weeks
|
Measured using the validated Peyronie's Disease Questionnaire (PDQ) subdomain symptom bother.
Four questions to evaluate pain or discomfort during vaginal intercourse: responses include "not at all bothered", "a little bit bothered" , "moderately bothered", "very bothered", "extremely bothered"
|
Baseline, 6 weeks
|
Change in penetrative sexual intercourse
Time Frame: Baseline, 6 weeks
|
Measured using self-reported question: "Over the past 4 weeks: When you attempted intercourse, how often were you able to penetrate (enter) your partner?"
Responses include "no sexual activity", "almost never or never" , "a few times (less than half the time)", "sometimes (about half the time)", "Most times (more than half the time)", "almost always or always.
|
Baseline, 6 weeks
|
Surgical straightening intervention
Time Frame: 6 weeks
|
Number of subjects to require surgical straightening
|
6 weeks
|
Change in erectile function
Time Frame: Baseline, 6 weeks
|
Measured using the International Index of erectile Function
|
Baseline, 6 weeks
|
Change in Erectile Function Domain (IIEF-EF)
Time Frame: Baseline, 6 weeks
|
Baseline, 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Tobias Kohler, MD, Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 19, 2024
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
September 26, 2023
First Submitted That Met QC Criteria
September 26, 2023
First Posted (Actual)
October 4, 2023
Study Record Updates
Last Update Posted (Actual)
April 16, 2024
Last Update Submitted That Met QC Criteria
April 12, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23-002478
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Erectile Dysfunction
-
Cairo UniversityRecruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Simple Prostatectomy | Erectile Dysfunction With Diabetes Mellitus | Erectile Dysfunction Due to Arterial Disease | Erectile Dysfunction Due to Injury | Erectile Dysfunction Due to Neuropathy and other conditionsEgypt
-
University of VirginiaActive, not recruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Erectile Dysfunction Due to General Medical Condition | Erectile Dysfunction Due to Arterial InsufficiencyUnited States
-
University of BaghdadCompletedSexual Dysfunction | Erectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Sexual Abstinence | Erectile Dysfunction With Diabetes Mellitus | Sexual Desire Disorder | Erectile Dysfunction Following Cryotherapy | Erectile Dysfunction... and other conditionsIraq
-
BayerCompletedSexual Dysfunction | Male Erectile DysfunctionBelgium, Italy, France, Germany, Spain, Netherlands, South Africa
-
Cairo UniversityCompletedVasculogenic Erectile DysfunctionEgypt
-
InitiaTerminatedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionCzech Republic, Lithuania, Netherlands, Palestinian Territories, Occupied
-
Rexahn Pharmaceuticals, Inc.CompletedErectile Dysfunction (ED)United States
-
SK Chemicals Co., Ltd.TerminatedMale Erectile Dysfunction
Clinical Trials on Collagenase Clostridium Histolyticum
-
Stony Brook UniversityCompletedAdhesion of Flexor Tendon of HandUnited States
-
Endo PharmaceuticalsCompletedEdematous SkinUnited States
-
Zachary GerutAdvance Biofactures CorporationCompleted
-
Endo PharmaceuticalsCompleted
-
Endo PharmaceuticalsCompletedLaxity; Skin | Cellulite | Edematous Fibrosclerotic PanniculopathyUnited States
-
Advance Biofactures CorporationCompletedLeiomyoma | Fibroids, UterineUnited States
-
Endo PharmaceuticalsCompletedCellulite | Edematous Fibrosclerotic PanniculopathyUnited States
-
Endo PharmaceuticalsCompletedCellulite | Edematous Fibrosclerotic PanniculopathyUnited States
-
Endo PharmaceuticalsCompletedEdematous Fibrosclerotic PanniculopathyUnited States
-
University of MiamiEndo PharmaceuticalsRecruitingSexual Dysfunctions, Psychological | Genital Diseases, Male | Peyronie DiseaseUnited States